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Abstract²At early drug discovery, purified protein-based 
assays are often used to characterise compound potency. As far 
as dose response is concerned, it is often thought that a time-
independent inhibitor is reversible and a time-dependent 
inhibitor is irreversible. Using a simple kinetics model, we 
investigate the legitimacy of this. Our model-based analytical 
analysis and numerical studies reveal that dose response of an 
irreversible inhibitor may appear time-independent under 
certain parametric conditions. Hence, time-independence cannot 
be used as evidence for inhibitor reversibility. Furthermore, we 
also analysed how the synthesis and degradation of a target 
receptor affect drug inhibition in an in vitro cell-based assay 
setting. Indeed, these processes may also influence dose response 
of an irreversible inhibitor in such a way that it appears time-
independent under certain conditions. Hence, time-independent 
dose response in a cell assay also needs careful considerations. It 
is necessary to formulate a suitable model for analysis of protein-
based assay and in vitro cell assay data to ensure a consistent 
understanding. 
Keywords²irreversible inhibition; model of receptor turnover; 
fast drug process; slow drug process; time-scale analysis 
I.  INTRODUCTION  
Drug discovery and development typically involve protein-
based assay, in vitro cell assay, in vivo animal assay and 
clinical trials. These studies are often organised in this 
particular temporal order, in the hope that the results of a 
previous step (e.g. protein-based assay) will help inform the 
design and interpretation of the subsequent experiment (e.g. in 
vitro cell assay).  
A new paradigm that helps enable robust translation of 
each type of study arises in recent years [1]. Known as 
Systems Pharmacology, it employs multi-scale modelling 
approaches to integrate heterogeneous types of data generated 
under diverse experimental conditions spanning different 
temporal and dimensional scales [2]. These models are able to 
reconcile different experimental conditions, such as in vitro 
cell assays and in vivo animal models [3], and to bridge 
preclinical models with clinical trials with an endeavour to 
generate statistically robust predictions that are validated with 
preclinical and clinical data [4].  
While multi-scale modelling has been successfully 
deployed in drug development programmes, its application in 
early drug discovery has been more limited [5]. In fact, there 
is an urgent need to develop Systems Pharmacology so as to 
better bridge protein-based assay and in vitro cell assay [1].  
Cellular kinetics may sometimes not be fully appreciated 
by medicinal chemists who design protein-based assays, and 
this limits its application. For instance, the potency of a 
chemical entity to inhibit an enzyme is often characterised by 
IC50, the chemical concentration that generates half of 
maximal inhibition. For an irreversible inhibitor that 
covalently modifies a purified target enzyme in vitro, the 
chemical reaction tends more complete given a longer drug 
incubation period. Consequently, IC50 usually exhibits 
incubation time-dependent shift, making the inhibitor appear 
more potent at long incubation periods [6, 7]. 
In contrast, a target protein in a living cell undergoes 
synthesis and degradation, which are often regulated via gene 
regulations and cell signalling. These processes typically 
happen within minutes and hours [8]. This may influence 
cellular response to drug inhibition. In other words, shooting a 
moving target in a cell might be different from shooting an 
immobile target in a protein-based assay. In this study, we 
investigate how cellular response is influenced by both drug 
parameters and cell parameters.  
II. A MODEL OF RECEPTOR TURNOVER AND IRREVERSIBLE 
INHIBITION 
A simple model is proposed to recapitulate receptor turnover 
(i.e. synthesis and degradation) and drug inhibition.  
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In process (1), receptor R is synthesized at a constant rate pk , 
and degrades following a first-order kinetics with a rate 
constant dk  For the sake of simplicity, this model does not 
consider feedback mechanism that regulates either synthesis or 
degradation. In process (2), a drug molecule first binds R 
reversibly to comprise an intermediate complex C with 
apparent association and dissociation rates onk  and offk , 
respectively. The complex C then forms a covalent bound 
irreversibly at the second step, in a first-order reaction with a 
rate constant ik ୧ . Based on mass-balance principle, the 
corresponding ordinary differential equations (ODEs) for 
concentrations of R and C are  
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with the following units: nM for R, C; nM/min for pk ; and 
1/min for dk , onk , offk  and ik . 
In the absence of drug, the receptor has a steady state at 
0 p dR k k  nM. Scaling R and C with 0R , they become 
dimensionless 0 d pr R R Rk k  , 0 d pc C R C k k  . 
ODEs (3) and (4) are written as 
 d
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This model takes a dimensionless form, when offk  is used to 
scale the time term by offk tW  , and to scale reaction rates by
on on offk kN  , i i offk kN  , and d d offk kN  . 
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Note all terms in (7) and (8) are dimensionless, including 
concentration variables r and c, time W ɒ, and parameters onN , 
iN , dN . The synthesis rate pk  is included in dN  through 
scaling  0d d off p offk k k k RN   . The initial conditions of 
this model are set to be  0 0 1r r   and  0 0 0c c  .  
With this dimensionless model, the analysis of system 
behaviour under different parametric regimes can be discussed 
in a consistent scheme. 
III. FAST DRUG PROCESS RELATIVE TO RECEPTOR 
TURNOVER 
The parametric regimes have been divided into that of fast 
drug process and slow drug process. We first discuss the 
conditions of fast drug binding and dissociation. 
A. Fast Drug Binding and Dissociation Relative to Receptor 
Turnover 
The parametric regime is defined by ݇௢௙௙ ب ݇ௗ ǡ  and ݇௢௡ ب ݇ௗ. In this case, the receptor turnover rate dk  is much 
smaller than the drug binding and dissociation rates ݇௢௡  and ݇௢௙௙.  
  When ݇௢௙௙ ب ݇ௗ, i.e., ߢௗ ا  ?ǡthe period of target coverage 
(characterized by  ? ௢݇௙௙ ? ) is much shorter than that of 
receptor degradation (characterized by  ? ௗ݇ ? ), which can 
be due to: i) short target coverage, i.e., ݇௢௙௙ ب  ?; ii) slow 
receptor degradation, i.e., ݇ௗ ا  ?; and iii) combination of 
i) and ii). 
Ь When ݇௢௡ ب ݇ௗ , i.e., ߢ௢௡ ب ߢௗ ǡ  a receptor binds a drug 
molecule at a rate much faster than its degradation.  
Under these conditions, the term of dN  can be ignored, and 
the model is approximated by 
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How small does dk  have to be in comparison to offk  and 
onk to ensure the validity of this approximation? This is 
examined by the following numerical simulation. Firstly, the 
full model in (7) and (8) are simulated with 1onN   ( on offk k 
) and 0.001iN   (݇௢௙௙ ب ݇௜), when 610dN   (Fig. 1(a)), and 
410dN   (Fig. 1(b)), respectively. The approximated model 
in (9) is simulated using identical values for onN  and iN , as 
shown in Fig. 1(c). All simulations are performed for four 
different incubation time periods, including 10-3, 1, 103 and 
106. It can be observed that the responses in Fig. 1(a) are close 
to those in Fig. 1(c), which suggests that when ߢௗ ൑  ? ?ି଺ , 
model (9) provides a good approximation to the full model in 
(7) and (8).  
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(c) Approximate model at 0dN    
Fig. 1. Dose response curves predicted for different incubation time, when ݇௢௡ ൌ  ? and ݇௜ ൌ  ?Ǥ ? ? ?. Incubation times shown in the figure legend (10-3, 
100, 103, 106) are in ߬. (a) Full model (7) and (8) simulated at 610dN  ; (b) 
Full model simulated at 410dN  ; (c) Simulation from the approximate 
model in (9). In all figures, ݇௢௡ is plotted in log10 scale. 
Denoting > @Tr c X , the simplified model in (9) can be 
written as a homogeneous system model,  
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We can use the eigenvalue method to analyse this system. 
Denoting the trace and determinant of matrix A as 
 trace( ) 1 on iT A N N     , det( ) on iA N N'    , the 
eigenvalues of A are calculated by  21,2 4 2T TO  r  ' . 
For 
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T TO   ' , the associated eigenvector is  ݒଵ ൌ ሾݒଵଵݒଵଶሿ் ൌ ቂଵା఑೔ି఑೚೙ାඥሺଵା఑೚೙ା఑೔ሻమିସ఑೚೙఑೔ଶ఑೚೙  ?ቃ். 
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T TO   ' , the associated eigenvector is  ݒଶ ൌ ሾݒଶଵݒଶଶሿ் ൌ ቂଵା఑೔ି఑೚೙ିඥሺଵା఑೚೙ା఑೔ሻమିସ఑೚೙఑೔ଶ఑೚೙  ?ቃ். 
With initial conditions ݎ଴ ൌ  ? and ܿ଴ ൌ  ?, the analytical 
solutions for (10) are  
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The log10 transformed ratio of the two eigenvalues for 
different pairs of ߢ௢௡ and ߢ௜ is plotted in a heat map (Fig. 2). 
This diagram shows that when both parameters have similar 
values and are above 1, ߣଵ and ߣଶ are close to each other (the 
red area in Fig. 2). In this case, the system has only one time 
scale in this parametric regime. However, if either parameter 
is much larger than 1 or both parameters are much smaller 
than 1, then ȁߣଵȁ ȁߣଶȁ ? ا  ? (the blue area in Fig. 2), and two 
different time scales exist, including a slow time scale 
characterized by 11 O  and a fast time scale characterized by 
21 O  (note T is negative).  
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Fig. 2. ଵ଴ሺߣଵ ߣଶ ? ሻ plotted as a function of ଵ଴ሺߢ௢௡ሻ and ଵ଴ሺߢ௜ሻ. Values 
between -10 and 0 are colour-coded. 
In the following, we will study several special cases within 
this parametric regime. 
B. Fast Drug Dissociation Relative to Covalent Modification 
Under the condition of fast drug process over receptor 
turnover (݇௢௙௙ ب ݇ௗǡ and ݇௢௡ ب ݇ௗ), we further consider the 
regime of ݇௢௙௙ ب ݇௜ ǡ i.e., ߢ௜ ا  ?. This means the drug 
dissociation is much faster than the covalent modification. 
This corresponds to the lower part of Fig. 2. This condition is 
satisfied if a) an irreversible inhibitor has to overcome a 
relatively large energy barrier to covalently modify the 
receptor, b) drug dissociation is rapid, c) a combination of 
both. The model can be further simplified as 
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In this case, d d
d d
r c
W W  . Hence, ȁ ?ȁ ȁܶଶȁ ? ا  ?. This means ȁߣଵȁ ൎ  ? and ȁߣଵȁ ا ȁߣଶȁ . In this case, two different time 
scales exist, a slow time scale characterized by 11 O  and a 
fast time scale characterized by 21 O . The receptor decreases 
in both time scales. 
Denote the scaled incubation times at which two dose 
response curves are measured by ߬ଵǡ ߬ଶǡ  respectively. If 
measurements are taken at incubation times comparable to or 
much longer than the slow time scale, (i.e. ߬ଵǡଶ ?  ? ȁߣଵȁ ?  or ߬ଵǡଶ ب  ? ȁߣଵȁ ? ), then dose responses are mainly determined by 
changes at the slow time scale. Time-dependency is evident if ߬ଵ ب ߬ଶ  and vice versa. This indicates that dose response 
curves for different incubation times should be separated. On 
the other hand, for much shorter incubation times, ߬ଵǡଶ ا ? ȁߣଶȁ ? , dose responses are mainly dependent on changes at the 
fast, shorter time scale  ? ȁߣଶȁ ? . The two dose response curves 
are well separated if ߬ଵ ب ߬ଶ , and vice versa. In contrast, if  ? ȁߣଶȁ ? ൏ ߬ଵǡଶ ൏  ? ȁߣଵȁ ? , then dose responses are determined 
by both time scales. For  ? ȁߣଶȁ ? ا ߬ଵǡଶ ا  ? ȁߣଵȁ ? , dose 
response curves are close to each other following one time 
scale.  
For example, suppose ߢ௢௡ ൌ  ?ǡ ߢ௜ ൌ  ?Ǥ ? ? ?. Then, ܶ ൌ െ ?Ǥ ? ? ?,  ?ൌ  ?Ǥ ? ? ?, ߣଵ ൌ െ ?Ǥ ? ൈ ? ?ିସ , ߣଶ ൌ െ ?Ǥ ?. ݒଵ ൎ ሾ ?Ǥ ?  ?ሿ୘, ݒଶ ൎ ሾെ ?Ǥ ?  ?ሿ୘Ǥ Therefore, the time scales 
are O(3) ( ? ȁߣଵȁ ? ൌ  ?Ǥ ? ൈ ? ?ଷ) and O(1) ( ? ȁߣଶȁ ? ൎ  ?Ǥ ? ?). The 
analytical solution to the receptor concentration is 
approximately ݎሺ߬ሻ ൌ  ?Ǥ ?ሺ ?Ǥ ?݁ିଶǤ଴ఛ ൅  ?Ǥ ?݁ି଴Ǥ଴଴଴ହఛሻ  under 
these parameters. 
For ߬ଵ ൌ  ?Ǥ ? ? ?ǡ ߬ଶ ൌ  ?, dose responses are dominated by 
the short time scale O(1). In addition, these incubation times 
are of three orders of magnitude difference. For the same 
input, dose response curves are expected to be separated 
(compare the two curves on the left in Fig. 1(c)). Using similar 
reasoning, dose response curves for ߬ଵ ൌ  ? ൈ ? ?ଷǡ ߬ଶ ൌ  ? ൈ
 ? ?଺ are expected to be separated, as both of them are mainly 
dependent on the fast time scale O(3) (the two curves on the 
right in Fig. 1(c)). For ߬ଵ ൌ  ?ǡ ଶ߬ ൌ  ? ? ? ?, dose response curve 
taken at  ? ൈ ௢݇௙௙ is mainly determined by the fast time scale ݁ିଶൈଵ , while the one taken at  ? ? ? ?ൈ ݇௢௙௙  is mainly 
determined by the slow time scale ݁ି଴Ǥ଴଴଴ହൈଵ଴଴଴ . Therefore, 
both dose response curves are close to each other (the two 
curves in the middle of Fig. 1(a)). 
In summary, for an irreversible inhibitor that dissociates 
quickly or has to overcome a large energy barrier to covalently 
modify a receptor, if the receptor undergoes very slow 
synthesis and degradation, two time scales exist for dose 
response. Dose response curves measured at different 
incubation times can be either close to each or widely 
separated, depending on the incubation time relative to the two 
time scales. Therefore, incubation time-independence in dose 
response does not necessarily suggest drug inhibition is 
reversible. 
In practice, if ݇௜ ا ݇௢௙௙  is known beforehand, the drug 
should be incubated for a period of time that is comparable to  ? ௜݇ ? . Then ߬ଵ and ߬ଶ are more likely to be in the long range, 
say ߬ଵǡଶ ب  ? ?ଷ ൈ ݇௢௙௙ . This leads to time-dependent dose 
responses and avoids confusion of taking the drug as a 
reversible inhibitor. 
C. Fast Drug Binding/Dissociation and Fast Covalent 
Modification Relative to Receptor Turnover 
The parametric regime is classified by: ݇௢௡ ب ݇ௗ ǡ݇௢௙௙ ب݇ௗ ǡ , ݇௜ ب ݇ௗ , and ݇௜ ൎ  ݇௢௡ . In this case, both reversible 
binding/dissociation and irreversible modification are faster 
than receptor turnover. The approximate model is the same as 
(9). According to Fig. 2, ߣଵ  and ߣଶ  are close to each other. 
Hence, the system has only one time scale that is 
approximately ܱሺȁߣଵȁିଵሻ (and equally ܱሺȁߣଶȁିଵሻ). Therefore, 
dose response curves measured at different incubation times 
are predicted to be separated from each other (Fig. 3). 
 
r
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Fig. 3. Dose response curves predicted for different incubation times. 
Incubation times shown in the figure legend (10-3, 100, 103, 106) are in ߬ , ݇௜ ൌȀ݇ௗ ൌ  ? ?.  
IV. SLOW DRUG PROCESS RELATIVE TO RECEPTOR 
TURNOVER 
A. Slow Drug Dissociation Relative to Receptor Turnover 
The parametric regime is defined by ݇௢௙௙ ا ݇ௗ , i.e., ߢௗ ب  ?. The target coverage rate is much slower than the 
receptor degradation rate, which can be due to: i) long period 
of target coverage; ii) fast receptor degradation; and iii) 
combination of both. This might be biologically relevant when 
receptor homeostasis is tightly regulated at the turnover level. 
The full model in (7) and (8) is used for this condition. 
This is an inhomogeneous system, which cannot be simply 
analysed by eigenvalue methods. To avoid using tedious 
mathematical formulation in the discussion, numerical studies 
are performed to analyse the dose response behaviour. 
Similar to Fig. 2, we have plotted ଵ଴ሺߣଵ ߣଶ ? ሻ as a 
function of ߢ௢௡  and ߢ௜  in log10 scales. For ݇௢௙௙ ൌ ݇ௗ , 
separation of time scales happens if either ݇௢௡ ب ݇ௗ  or ݇௜ ب ݇ௗ , with the former leads to more pronounced effects 
(Fig. 4(a)). In contrast, if ݇௢௙௙ ൌ  ?Ǥ ? ? ?݇ௗ, separation of time 
scales can also happen if both ݇௢௡ ا ݇ௗ and ݇௜ ا ݇ௗ(bottom-
left area in Fig. 4(b)). 
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(a) ݇௢௙௙ ൌ ݇ௗ 
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(b) ݇௢௙௙ ൌ  ?Ǥ ? ? ?݇ௗ 
Fig. 4. ଵ଴ሺɉଵ ɉଶ ? ሻ plotted as a function of Ɉ୭୬  and Ɉ୧ . (a) ݇௢௙௙ ൌ ݇ௗǢ (b) ݇௢௙௙ ൌ  ?Ǥ ? ? ?݇ௗ. Both axes are in log10 scale. Values between -10 and 0 are 
colour-coded. 
To examine whether separation of time scales dictates 
time-dependency in dose response, we need to investigate how 
the factors associated with the exponential functions in 
UHFHSWRU¶V DQDO\WLFDO VROXWLRQ FRPSDUH WR HDFK RWKHU )LJ. 5 
plots ଵ଴ሼȁݒଵଵߣଶሺ ? ൅ ߣଵሻ ሾݒଶଵߣଵሺ ? ൅ ߣଶሻሿ ? ȁሽ as a function of ߢ௢௡  and ߢ௜  in log10 scales. Fig. 5(a) shows when ݇௢௙௙ ൌ ݇ௗ , 
the two factors are comparable for the following regimes:  
i) ݇௢௡ ൐ ݇ௗ, ݇௜ ൐ ݇ௗ, ݇௢௡ ൎ ݇௜Ǣ 
ii) ݇௢௡ ൏ ݇ௗ, ݇ௗ ൏ ݇௜ ൏  ? ?݇ௗ; 
iii) ݇௜ ൏ ݇ௗ, ଵ଴ሺ݇௢௡ሻ ൏ െ ଵ଴ሺ݇௜ሻ. 
Considering both Fig. 4(a) and Fig. 5(a), the only parametric 
regime that allows separation of time scales and also has 
comparable factors in front of exponentially decay factors is: ݇௢௙௙ ൌ ݇ௗ , ݇௜ ൏ ݇ௗ , ݇௢௡ ൐ ݇ௗ , ଵ଴ሺ݇௢௡ሻ ൏ െ ଵ଴ሺ݇௜ሻ . 
This is the region marked by dashed triangles in Fig. 4(a) and 
5(a).  
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(b) ݇௢௙௙ ൌ  ?Ǥ ? ? ?݇ௗ 
Fig. 5. ଵ଴ሼȁଵଵɉଶሺ ? ൅ ɉଵሻ ሾଶଵɉଵሺ ? ൅ ɉଶሻሿ ? ȁሽ plotted as a function of Ɉ୭୬ 
and Ɉ୧ . (a) ݇௢௙௙ ൌ ݇ௗǢ  (b) ݇௢௙௙ ൌ  ?Ǥ ? ? ?݇ௗ . Both axes are in log10 scale. 
Values between -15 and 10 are colour-coded. 
 
An example is discussed to illustrate these ideas by taking ݇௢௙௙ ൌ ݇ௗ, ݇௜ ا ݇ௗ. This means the receptor degradation is as 
fast as target coverage and the drug overcomes a large energy 
barrier to covalently modify the receptor.  
Suppose ݇௢௡ ൌ ݇ௗǡ ݇௜ ൌ  ?Ǥ ? ? ?݇ௗ . Under this condition, 
the drug-associated receptor complex continues to rise over 
time before reaching its equilibrium state. Accordingly, 
complex dissociation rate keeps increasing until the new 
equilibrium is reached. Hence, receptor first decreases as a 
result of drug inhibition, then recovers to a point that is just 
below the initial condition due to complex dissociation. 
Apparently, dose response measured before recovery would 
make the drug appear more potent than the actual steady-state 
response (compare dotted curve with other curves in Fig. 6). 
Given the proximity between ȁߣଵȁ  and ȁߣଶȁ , dose response 
measurement taken at an incubation time that is longer than  ? ȁߣଵȁ ?  are predicted to be close to each other. 
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Fig. 6. Dose response curves predicted for different incubation time. (a) 
Full model is simulated, assuming ݇௢௙௙ ൌ ݇ௗǡ ݇௜ ൌ  ?Ǥ ? ? ?݇ௗǤ Incubation 
times (10-3, 100, 103, 106) are in ߬. 
 
Alternatively, when ݇௢௡ ൌ  ? ? ? ? ?݇ௗ ǡ ݇௜ ൌ  ?Ǥ ? ? ?݇ௗ, then, ܶ ൌ െ ? ? ? ? ?Ǥ ? ? ?,  ?ൌ ? ?Ǥ ? ? ?, ߣଵ ൎ െ ?Ǥ ? ൈ ? ?ିଷ , ߣଶ ൎെ ?Ǥ ? ൈ ? ?ସ, ݒଵ ?ሾ ?Ǥ ? ൈ ? ?ିସ  ?ሿ், ݒଶ ?ሾെ ?Ǥ ? ൈ ? ?଴  ?ሿ் Ǥ  ݎሺݐሻ ൌ  ?Ǥ ? ൈ ? ?ିଶ ?Ǥ ? ൈ ? ?଴ ൈ ݁ିଵǤ଴ൈଵ଴ర௧ െ  ?Ǥ ?ൈ  ? ?ିଶ݁ିଵǤଵൈଵ଴షయ௧ 
Because ߣଵ ا ߣଶ, only the fast time scale ߣଶ determines 
dose response. Therefore, dose response is incubation time-
dependent. 
B. Slow Drug Binding and Fast Covalent Modification 
Relative to Receptor Turnover 
The parametric regime is:݇௢௡ ا ݇ௗ ا ݇௜, (upper left corner 
of Fig. 2). This speaks about an irreversible inhibitor that 
binds slowly to the receptor but reacts covalently in a fast 
manner, both relative to receptor degradation. The simplified 
model is accordingly 
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                                     (12) 
Similar to the previous case, two different time scales exist for 
model (12), and the receptor decreases in both time scales.  
V. CONCLUSIONS 
At lead generation and optimisation, it is important to 
understand the Mechanism Of Action (MOA) of a chemical 
compound, as well as the Structure-Activity Relationship 
(SAR), in the hope that ultimately a compound with sufficient 
therapeutic efficacy is taken further for preclinical 
development. Reversibility of a compound is a crucial aspect 
of MOA characterisation, which is often unknown for 
compounds coming out of empirical screening methods.  
Towards this goal, assays have been established to study 
inhibition reversibility [9]. It is generally accepted that 
response to irreversible inhibitors are time-dependent. Hence, 
it is often taken for granted that time-independence indicates 
inhibition reversibility. However, our mathematical analysis 
refutes this. Based on our simulation, for protein-based assays, 
under certain parameter conditions, the dose response curves 
can be very similar to each other (compare the middle curves 
in Fig. 1(C)), given 1000-fold variation in incubation time. In 
practice, these data might not be statistically different and can 
be erroneously taken as evidence of reversible inhibitor. 
Our ensuing analysis showed that active receptor synthesis 
and degradation also have implications in dose response. For 
instance, in Fig. 6, it is shown that when a slowly-dissociating 
irreversible drug is applied to a receptor under fast turnover, 
dose response may be highly similar to each other under a 
variety of incubation periods. Together with the previous 
example, it is inappropriate to conclude a drug is reversible 
given time-independent dose response either based on protein 
assay or in vitro cell assay. 
The main purpose of this analysis is to demonstrate the 
relationship between dose response and parameter values. For 
the sake of simplicity, we only considered a linear model in 
which each reaction follows first-order kinetics. Results 
obtained in this paper are specific to the form of this linear 
model. In addition, we did not consider biological regulation 
over synthesis, degradation and sub-cellular localisation of a 
receptor [8]. In reality, receptor is often regulated under 
different levels, which often necessitates mechanistic 
modelling of a biological pathway to aid in interpretation of in 
vitro cell assays.  
To further translate in vitro results into in vivo knowledge, 
Target Mediated Drug Disposition (TMDD) Models were 
developed to analyse receptor pharmacokinetics (PK) and 
pharmacodynamics (PD) in recent years. In addition to drug 
binding and receptor turnover, these models also consider the 
elimination of all species, to mimic in vivo conditions. They 
can be served as a useful theoretical framework. Model-based 
analysis revealed that the necessary and sufficient condition 
for receptor rebound in a single dose animal experiment is that 
elimination rate of the drug-receptor product being slower than 
the elimination rates of the drug and of the receptor [9]. A 
time-scale analysis was also performed to provide accurate 
approximations of the temporal evolution under the 
assumption of high drug binding affinity [10]. These models 
share some parameters with the in vitro model described in 
this paper. For a drug discovery and development programme, 
the in vitro model should be used to identify parameter values 
from in vitro data. These parameters can be used subsequently 
to help identify the remaining parameter values in the in vivo 
model. This step-wise fitting may reduce uncertainty in 
parameter estimation. In this context, the in vitro model 
described in this paper improves the utility of TMDD models.  
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